SDGR Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

83.22M

-5.78%

-0.183

-66.75%

72.55M

+21.83%

-0.490

-40.24%

64.21M

+17.25%

-0.623

+5.65%

Estimates Revision

The market is revising Downward the revenue expectations for Schrödinger, Inc. (SDGR) for FY2025, with the revenue forecasts being adjusted by -0.02% over the past three months. During the same period, the stock price has changed by -3.62%.

Revenue Estimates for FY2025

Revise Downward

-0.02%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-12.78%

In Past 3 Month

Stock Price

Go Down

-3.62%

In Past 3 Month

6 Analyst Rating

Wall Street analysts forecast SDGR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SDGR is 26.50 USD with a low forecast of 21.00 USD and a high forecast of 33.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

2 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

21.00

Averages

26.50

High

33.00

Current: 0.000

Low

21.00

Averages

26.50

High

33.00

Morgan Stanley

Equal Weight

maintain

$18 -> $19

2026-01-08

New

Reason

Morgan Stanley

Price Target

$18 -> $19

2026-01-08

New

maintain

Equal Weight

Reason

Morgan Stanley raised the firm's price target on Schrodinger to $19 from $18 and keeps an Equal Weight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech's outperformance in 2026 as commercial names transition from "capital consumers to producers" and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.

KeyBanc

Overweight

downgrade

$28 -> $25

2026-01-08

New

Reason

KeyBanc

Price Target

$28 -> $25

2026-01-08

New

downgrade

Overweight

Reason

KeyBanc lowered the firm's price target on Schrodinger to $25 from $28 and keeps an Overweight rating on the shares. Coming off a choppy year for HCIT stocks, fundamentally, the firm did see a "year of inflection" for many of its names with estimate revisions plus valuations largely bottoming. While KeyBanc expects momentum to continue for most of its coverage, the firm does see valuation multiples impacted by competition concerns and regulatory impacts.

TD Cowen

Brendan Smith

Buy

downgrade

$33 -> $24

2026-01-08

New

Reason

TD Cowen

Brendan Smith

Price Target

$33 -> $24

2026-01-08

New

downgrade

Buy

Reason

TD Cowen analyst Brendan Smith lowered the firm's price target on Schrodinger to $24 from $33 and keeps a Buy rating on the shares. The firm adjusted price targets in the diagnostic tools group group as part of a Q4 preview. Investor sentiment continues to inflect upward with 2026 guidance updates "key for positioning within the sector recovery," the analyst tells investors in a research note. TD is most positive on stocks "with clear multi-year frameworks and multiple avenues for upside to derisked growth assumptions."

UBS

Neutral

initiated

$18

2026-01-07

New

Reason

UBS

Price Target

$18

2026-01-07

New

initiated

Neutral

Reason

UBS initiated coverage of Schrodinger with a Neutral rating and $18 price target as the analyst initiated or assumed coverage on 22 small-to-mid cap biotech names. After a rough period, biotech fundamentals are now inflecting, contends the analyst, who expects investor confidence to recover and sees this positioning biotech for strong performance in 2026. Among the group, top picks include Apogee Therapeutics (APGE), Cogent Biosciences (COGT), Kodiak Sciences (KOD), Ideaya Biosciences (IDYA), Inventiva (IVA), SAB Biotherapeutics (SABS) and Ventyx Biosciences (VTYX), which the analyst highlights as having key upcoming catalysts, de-risked best-in-class portfolios, strong data, and broader pipelines.

BofA

Neutral -> Buy

upgrade

2025-12-15

Reason

BofA

Price Target

2025-12-15

upgrade

Neutral -> Buy

Reason

BofA upgraded Schrodinger to Buy from Neutral.

BofA

Michael Ryskin

Neutral -> Buy

upgrade

$24

2025-12-15

Reason

BofA

Michael Ryskin

Price Target

$24

2025-12-15

upgrade

Neutral -> Buy

Reason

As previously reported, BofA analyst Michael Ryskin upgraded Schrodinger to Buy from Neutral with an unchanged price target of $24. Recent quarterly results underscore resilience despite market noise, says the analyst, who sees a more favorable backdrop for Pharma and R&D spending while also citing Schrodinger's strategic pivot toward its core strengths in Discovery and Software.

Valuation Metrics

The current forward P/E ratio for Schrodinger Inc (SDGR.O) is -9.24, compared to its 5-year average forward P/E of -15.87. For a more detailed relative valuation and DCF analysis to assess Schrodinger Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-15.87

Current PE

-9.24

Overvalued PE

4.90

Undervalued PE

-36.65

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-15.22

Current EV/EBITDA

-7.34

Overvalued EV/EBITDA

2.10

Undervalued EV/EBITDA

-32.54

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

13.27

Current PS

4.64

Overvalued PS

24.52

Undervalued PS

2.02

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

SDGR News & Events

Events Timeline

No data

News

3.5

01-09Newsfilter

Schrodinger Partners with Eli Lilly to Launch AI Drug Design Platform TuneLab

6.5

2025-12-26Yahoo Finance

Pinnacle Financial Partners Trading 32.3% Below Fair Value Amid Growth Prospects

3.5

2025-12-09PRnewswire

Avant Technologies Strengthens Clinical Validation for α-Klotho Therapy

People Also Watch

Frequently Asked Questions

What is Schrodinger Inc (SDGR) stock price today?

The current price of SDGR is 18.39 USD — it has decreased -1.18 % in the last trading day.

What is Schrodinger Inc (SDGR)'s business?

Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Its segments include Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor), and others. Its software has been used by researchers around the world at more than 1,818 academic institutions.

What is the price predicton of SDGR Stock?

What is Schrodinger Inc (SDGR)'s revenue for the last quarter?

Schrodinger Inc revenue for the last quarter amounts to 54.32M USD, increased 53.94 % YoY.

What is Schrodinger Inc (SDGR)'s earnings per share (EPS) for the last quarter?

Schrodinger Inc. EPS for the last quarter amounts to -0.45 USD, decreased -13.46 % YoY.

What changes have occurred in the market's expectations for Schrodinger Inc (SDGR)'s fundamentals?

How many employees does Schrodinger Inc (SDGR). have?

Schrodinger Inc (SDGR) has 891 emplpoyees as of January 10 2026.

What is Schrodinger Inc (SDGR) market cap?

Today SDGR has the market capitalization of 1.35B USD.